Theralase Technologies (TLT) AI Stock Analysis

• Market Cap: C$48.84M
• Dividend Yield: N/A
• Average Volume (3M): 63.01K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.21
• Revenue Growth: 16.00%
• EPS Growth: 9.79%
• Country: CA
• Employees: 14
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 257,058,320
• 10 Day Avg. Volume: 68,281
• 30 Day Avg. Volume: 63,009
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.70
• Price Target Upside: 268.42% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Theralase Technologies' overall stock score is primarily influenced by its weak financial performance and bearish technical indicators. While the company has promising clinical developments and strategic plans, these are overshadowed by ongoing financial struggles and negative market momentum.

Theralase Technologies Business Overview & Revenue Model

Company Description

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.

How the Company Makes Money

Theralase Technologies generates revenue through the sale of its laser therapy systems and related accessories to healthcare providers, clinics, and hospitals. The company also earns income from the development and commercialization of its photodynamic therapy technologies, which are aimed at treating cancer. These revenue streams are supported by strategic partnerships and collaborations with research institutions and healthcare organizations to advance clinical trials and expand the market reach of its innovative therapies. Additionally, Theralase may engage in licensing agreements for its proprietary technologies, providing another potential source of income.

Theralase Technologies Financial Statement Overview

Summary

Theralase Technologies faces significant financial challenges, with declining revenues, persistent losses, and negative cash flows. Despite low leverage, the reliance on external financing and negative profitability metrics indicate a need for strategic improvements.

Income Statement

Theralase Technologies has been experiencing declining revenue over the past few years, with a notable decrease from $1,138,569 in 2022 to $1,033,431 in 2024. The company has consistently reported negative net income, indicating ongoing losses. Gross profit margins have been low and deteriorating, reflecting challenges in cost management. The negative EBITDA and EBIT margins further highlight operational inefficiencies and lack of profitability.

Balance Sheet

The balance sheet shows a weakening position, with declining total assets and stockholders' equity over the years. The debt-to-equity ratio remains low due to minimal debt, which is a positive aspect. However, the equity ratio is declining, and the return on equity is negative due to continued losses, presenting a risk to financial stability.

Cash Flow

Theralase Technologies has been consistently generating negative operating cash flow and free cash flow, indicating struggles with generating cash from core operations. Free cash flow has shown some improvement in recent years but remains negative, highlighting cash management issues. Financing activities have been the primary source of cash, which could pose a risk if external funding becomes limited.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.07M	1.03M	1.07M	1.14M	780.64K	929.12K
Gross Profit	595.91K	554.03K	562.13K	628.17K	309.94K	269.68K
EBITDA	-3.99M	-3.96M	-4.25M	-4.90M	-4.31M	-5.56M
Net Income	-4.28M	-4.26M	-4.57M	-5.25M	-4.42M	-5.61M
Balance Sheet
Total Assets	3.02M	3.25M	3.28M	4.16M	5.94M	10.02M
Cash, Cash Equivalents and Short-Term Investments	46.33K	268.76K	43.91K	1.51M	3.69M	7.88M
Total Debt	244.87K	293.87K	386.88K	473.62K	35.72K	92.34K
Total Liabilities	1.74M	1.18M	1.37M	1.07M	874.79K	857.13K
Stockholders Equity	1.28M	2.07M	1.91M	3.09M	5.07M	9.16M
Cash Flow
Free Cash Flow	-3.29M	-3.35M	-4.11M	-5.20M	-4.13M	-4.61M
Operating Cash Flow	-3.20M	-3.33M	-4.07M	-5.13M	-4.03M	-4.45M
Investing Cash Flow	-91.34K	-19.97K	-37.27K	-70.41K	-100.82K	-164.58K
Financing Cash Flow	2.91M	3.57M	2.65M	3.02M	-57.37K	-57.56K

Theralase Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.19
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TLT, the sentiment is Negative. The current price of 0.19 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.21, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.21 is Neutral, neither overbought nor oversold. The STOCH value of 13.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TLT.

Theralase Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASG	60 Neutral	C$20.29M	―	-26.27%	―	17.61%	-19.19%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
TLT	45 Neutral	C$48.84M	―	-291.69%	―	16.00%	9.79%
VPT	44 Neutral	C$17.61M	―	207.08%	―	88.47%	11.88%
PINK	43 Neutral	C$26.74M	―	-233.44%	―	219.12%	-15.92%
BLOZF	―	$46.70M	―	-131.47%	―	―	―
TBRIF	―	$2.47M	―	-224.63%	―	―	―

Theralase Technologies Corporate Events

Theralase Technologies Closes Private Placement to Fund Cancer Treatment Research

Theralase Technologies Inc. has successfully closed a non-brokered private placement, raising approximately $CAN 672,627 through the issuance of 3,363,134 units. The proceeds will be used to advance their Phase II Non-Muscle Invasive Bladder Cancer clinical study, develop Rutherrin®, and for general corporate purposes. The offering is subject to final acceptance from the TSX Venture Exchange and includes related party transactions with certain insiders. The securities issued will be subject to a hold period under Canadian securities laws.

Theralase Technologies Extends Warrant Expiry to 2028

Theralase Technologies Inc. has announced the extension of the expiry date for 4,800,000 share purchase warrants from June 30, 2025, to June 30, 2028. This extension, pending final acceptance by the TSX Venture Exchange, allows the company more time to leverage these financial instruments as it continues its development of innovative therapeutics, potentially impacting its market positioning and stakeholder interests.

Theralase Completes $CAN 571,000 Private Placement to Advance Cancer Research

Theralase Technologies Inc. has successfully completed a non-brokered private placement, raising approximately $CAN 571,000 through the issuance of 2,855,000 units. The funds will be used to advance their Phase II clinical study on Non-Muscle Invasive Bladder Cancer, develop Rutherrin®, and for general corporate purposes. The offering included related party transactions, with certain insiders participating, and is subject to final acceptance from the TSX Venture Exchange.

Theralase Completes Annual Meeting, Outlines Future Goals

Theralase Technologies Inc. announced the successful completion of its Annual General and Special Meeting, where shareholders approved various resolutions. The company hosted a virtual presentation to outline strategic objectives and upcoming milestones, emphasizing its focus on accelerating the commercialization of its innovative therapeutic technologies. This development is part of Theralase’s mission to advance safe and effective treatments for cancer, bacteria, and viruses, reinforcing its commitment to stakeholders.

Theralase Technologies to Host Annual General Meeting with Virtual Engagement

Theralase Technologies Inc. has announced its upcoming Annual General and Special Meeting (AGSM) scheduled for June 11, 2025. The meeting will be held at their Toronto head office and will include a virtual presentation for shareholders unable to attend in person. This presentation will outline the company’s strategic objectives for 2025 and 2026 and provide a platform for shareholder engagement through a question and answer session. This initiative reflects Theralase’s commitment to transparency and shareholder involvement, potentially strengthening its industry position and stakeholder relations.

Theralase Reports Q1 2025 Financial Results Amid Ongoing Research Progress

Theralase Technologies reported a significant decline in revenue for the first quarter of 2025, with a 48% year-over-year decrease to $91,190. Despite increased research and development expenses to support ongoing studies, the company faced a net loss of $1,471,250. Operationally, Theralase completed two non-brokered private placements, raising funds to support its research programs. The company is advancing its Herpes Simplex Virus treatment program and has made progress in its Phase II bladder cancer study, with promising interim results showing a 62% complete response rate among patients.

Theralase to Unveil Promising Cancer Treatment Research at ASTRO 2025

Theralase Technologies Inc. is set to present groundbreaking research at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, showcasing promising preclinical results of their drug Rutherrin®. This ruthenium-based small molecule, when activated by radiation, demonstrates a dual-action strategy against cancer by inducing immediate cytotoxicity and stimulating a durable immune response. The study highlights Rutherrin®’s potential to enhance radiation therapy effectiveness, offering a major advancement in oncologic treatment. Theralase plans to complete GLP toxicology studies in 2025, aiming to launch clinical studies in early 2026 targeting aggressive cancers such as GBM, lung, pancreatic, lymphoma, and colorectal cancers.

Theralase Unveils Promising Cancer Treatment Results with Rutherrin

Theralase Technologies has announced promising preclinical results showing that its radiation-activated drug, Rutherrin, is significantly more effective than traditional radiation therapy in destroying cancer cells. The research, which will be presented at the ASTRO 2025 Annual Meeting, highlights Rutherrin’s ability to target tumors selectively, penetrate the blood-brain barrier, and activate a sustained immune response, potentially improving patient outcomes and overcoming treatment resistance.

Theralase Advances Cancer Treatment Studies with Promising Interim Results

Theralase Technologies has made significant progress in its Study II for BCG-unresponsive non-muscle invasive bladder cancer, with 91% of patient enrollment completed. The interim clinical data shows promising results, with a strong complete response rate and no serious adverse events reported. The company plans to complete enrollment by summer 2025 and submit a New Drug Application by 4Q2026. Additionally, Theralase is exploring international partnerships for the commercialization of its Ruvidar® treatment and has completed pre-clinical research for its use in treating glioblastoma multiforme brain cancer.